Michael J. Eblan

4.9k total citations · 3 hit papers
26 papers, 2.2k citations indexed

About

Michael J. Eblan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Michael J. Eblan has authored 26 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Surgery. Recurrent topics in Michael J. Eblan's work include Lysosomal Storage Disorders Research (5 papers), Cellular transport and secretion (3 papers) and Advanced Radiotherapy Techniques (3 papers). Michael J. Eblan is often cited by papers focused on Lysosomal Storage Disorders Research (5 papers), Cellular transport and secretion (3 papers) and Advanced Radiotherapy Techniques (3 papers). Michael J. Eblan collaborates with scholars based in United States, Switzerland and South Korea. Michael J. Eblan's co-authors include Andrew Z. Wang, Joseph M. Caster, Yuanzeng Min, Ellen Sidransky, Özlem Göker-Alpan, Joel E. Tepper, Tian Zhang, Benjamin G. Vincent, Laura E. Herring and Longzhen Zhang and has published in prestigious journals such as Chemical Reviews, Journal of Clinical Oncology and Nature Nanotechnology.

In The Last Decade

Michael J. Eblan

25 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Translation of Nanomedicine

2015 628 citations Yuanzeng Min, Joseph M. Caster et al. Chemical Reviews profile →
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy

2017 590 citations Yuanzeng Min, Kyle C. Roche et al. Nature Nanotechnology profile →
Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

2017 303 citations Kyle Wang, Michael J. Eblan et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael J. Eblan United States	13	878	524	460	424	417	26	2.2k
Владимир П. Баклаушев Russia	26	386 0.4×	375 0.7×	725 1.6×	318 0.8×	176 0.4×	157	2.2k
Lingjiao Zhang United States	28	509 0.6×	383 0.7×	835 1.8×	212 0.5×	782 1.9×	58	2.9k
Chunchao Xia China	26	608 0.7×	563 1.1×	343 0.7×	204 0.5×	96 0.2×	120	2.4k
Wanhai Xu China	35	892 1.0×	669 1.3×	1.8k 3.9×	626 1.5×	332 0.8×	139	3.5k
Guido Piontek Germany	26	363 0.4×	254 0.5×	684 1.5×	203 0.5×	311 0.7×	58	2.0k
Fei Kang China	25	739 0.8×	186 0.4×	386 0.8×	472 1.1×	326 0.8×	99	1.8k
Sylvie Roberge United States	18	654 0.7×	481 0.9×	1.1k 2.5×	201 0.5×	258 0.6×	39	2.5k
Marjan Rafat United States	22	659 0.8×	328 0.6×	820 1.8×	763 1.8×	673 1.6×	59	2.9k
Lu Liu China	29	787 0.9×	198 0.4×	1.1k 2.4×	193 0.5×	264 0.6×	94	2.6k
Colin F. Greineder United States	24	256 0.3×	373 0.7×	522 1.1×	253 0.6×	279 0.7×	66	1.5k

Countries citing papers authored by Michael J. Eblan

Since Specialization

Citations

This map shows the geographic impact of Michael J. Eblan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Eblan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Eblan more than expected).

Fields of papers citing papers by Michael J. Eblan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Eblan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Eblan. The network helps show where Michael J. Eblan may publish in the future.

Co-authorship network of co-authors of Michael J. Eblan

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Eblan. A scholar is included among the top collaborators of Michael J. Eblan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Eblan. Michael J. Eblan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Longzhen, Yuanzeng Min, Joseph M. DeSimone, et al.. (2020). Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. UNC Libraries. 7 indexed citations

Myung, Ja Hye, Michael J. Eblan, Joseph M. Caster, et al.. (2018). Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture. Clinical Cancer Research. 24(11). 2539–2547. 34 indexed citations

Wang, Kyle, Kevin A. Pearlstein, Allison M. Deal, et al.. (2017). Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiotherapy and Oncology. 125(2). 293–300. 89 indexed citations

Sud, Shivani, Jordan A. Holmes, Michael J. Eblan, Ronald Chen, & Ellen L. Jones. (2017). Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis. Gynecologic Oncology. 148(2). 349–356. 53 indexed citations

Min, Yuanzeng, Kyle C. Roche, Shaomin Tian, et al.. (2017). Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nature Nanotechnology. 12(9). 877–882. 590 indexed citations breakdown →

Wang, Kyle, Michael J. Eblan, Matthew B. Lipner, et al.. (2017). OA24.03 Cardiac Toxicity after Radiation for Stage III NSCLC: Pooled Analysis of Dose-Escalation Trials Delivering 70-90 Gy. Journal of Thoracic Oncology. 12(1). S339–S340. 1 indexed citations

Pearlstein, Kevin A., Panayiotis Mavroidis, Brian C. Jensen, et al.. (2017). Heart Dosimetric Analysis of Three Types of Cardiac Toxicity in Patients Treated on Dose-Escalation Trials for Stage III Non–small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 99(2). S152–S152. 5 indexed citations

Min, Yuanzeng, Joseph M. Caster, Michael J. Eblan, & Andrew Z. Wang. (2015). Clinical Translation of Nanomedicine. Chemical Reviews. 115(19). 11147–11190. 628 indexed citations breakdown →

Mosaly, Prithima, Łukasz Mazur, Seth Miller, et al.. (2014). Application of human factors analysis and classification system model to event analysis in radiation oncology. Practical Radiation Oncology. 5(2). 113–119. 6 indexed citations

10.

Mosaly, Prithima, Łukasz Mazur, Seth Miller, et al.. (2014). Assessing the Applicability and Reliability of the Human Factors Analysis and Classification System (HFACS) to the Analysis of Good Catches in Radiation Oncology. International Journal of Radiation Oncology*Biology*Physics. 90(1). S750–S751. 2 indexed citations

11.

Eblan, Michael J., Hanna K. Sanoff, Autumn J. McRee, et al.. (2014). A phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer.. Journal of Clinical Oncology. 32(15_suppl). TPS3667–TPS3667. 2 indexed citations

12.

Mosaly, Prithima, Łukasz Mazur, Seth Miller, Michael J. Eblan, & Ellen L. Jones. (2013). Applying Human Factors Analysis and Classification System (HFACS) to the Analysis of Good Catches in Radiation Oncology. International Journal of Radiation Oncology*Biology*Physics. 87(2). S683–S683. 2 indexed citations

13.

Eblan, Michael J. & Andrew Z. Wang. (2013). Improving chemoradiotherapy with nanoparticle therapeutics.. PubMed. 2(4). 320–329. 28 indexed citations

14.

Eblan, Michael J., Michael N. Corradetti, John N. Lukens, et al.. (2012). Brachial Plexopathy in Apical Non-Small Cell Lung Cancer Treated With Definitive Radiation: Dosimetric Analysis and Clinical Implications. International Journal of Radiation Oncology*Biology*Physics. 85(1). 175–181. 28 indexed citations

15.

Eblan, Michael J., Michael N. Corradetti, John N. Lukens, et al.. (2011). Brachial Plexopathy in Apical Non-small Cell Lung Cancer Treated with Definitive Radiation: Dosimetric Analysis and Clinical Implications. International Journal of Radiation Oncology*Biology*Physics. 81(2). S50–S51. 1 indexed citations

16.

Göker-Alpan, Özlem, Edythe Wiggs, Michael J. Eblan, et al.. (2008). Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease. The Journal of Pediatrics. 153(1). 89–94.e4. 38 indexed citations

17.

Ziegler, Shira G., Michael J. Eblan, Usha Gutti, et al.. (2007). Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Molecular Genetics and Metabolism. 91(2). 195–200. 87 indexed citations

18.

Göker-Alpan, Özlem, Benoit I. Giasson, Michael J. Eblan, et al.. (2006). Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 67(5). 908–910. 168 indexed citations

19.

Eblan, Michael J., Sonja W. Scholz, Barbara Stubblefield, et al.. (2006). Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism. Neuroscience Letters. 404(1-2). 163–165. 10 indexed citations

20.

Eblan, Michael J., Özlem Göker-Alpan, & Ellen Sidransky. (2005). PERINATAL LETHAL GAUCHER DISEASE: A DISTINCT PHENOTYPE ALONG THE NEURONOPATHIC CONTINUUM. Fetal and Pediatric Pathology. 24(4-5). 205–222. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact